NCT07419841 2026-03-16
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Compass Therapeutics
Phase 1 Not yet recruiting
Compass Therapeutics
Merck Sharp & Dohme LLC
AccSalus Biosciences, Inc.
OncoHost Ltd.
Telix Pharmaceuticals (Innovations) Pty Limited
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Power Life Sciences Inc.